Listing & Compliance Notices

Newton Golf Company, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1)).

“October 2, 2025, the Company also received a notice from Nasdaq, notifying the Company that, as a result of Ms. Pepper’s resignation, the Company is not in compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2). Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) provide a cure period for these deficiencies until the earlier of (i) the Company’s next annual stockholders’ meeting or (ii) September 29, 2026; however, if the Company’s next annual stockholders’ meeting is held before March 27, 2026, then the cure period will continue through March 27, 2026. The Company intends to appoint an”

OFFICE PROPERTIES INCOME TRUST received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“September 25, 2025, we received a notification letter from Nasdaq informing us that we have not regained compliance with Listing Rule 5450(a)(1) and that our common shares are subject to delisting from Nasdaq. If we do not appeal this determination in accordance with the Nasdaq Listing Rules, our common shares will be delisted at the opening of business on October 6, 2025. We do not expect to appeal this determination.”

LiveOne, Inc. received a nasdaq delisting notice notice regarding minimum bid price.

“September 25, 2025, the Company received a delist determination letter from the Staff advising the Company that the Staff had determined that the Company did not regain compliance with the Bid Price Rule by the September 24, 2025 deadline, and that the Company was not eligible for a second 180 day extension period due to the Company not meeting the minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market. Accordingly, unless the Company requested an appeal of this determination by October 2, 2025, the Staff had determined that the Company’s securities will be sche”

Skillz Inc. received a nyse extension granted notice regarding late filing (rules 802.01E).

“September 25, 2025, the NYSE granted the Company’s request for an Additional Cure Period and agreed to provide the Company with an extension to continue its listing on the NYSE through December 17, 2025, subject to NYSE’s ongoing reassessment and provided the Company becomes current with its SEC filings by such date. The Company continues to work diligently to complete and file the Delayed Filings as soon as reasonably practicable, which the Company expects to be in advance of the timing requirements set forth by the NYSE. Forward-Looking Statements This Current Report on Form 8-K includes “fo”

ClearSign Technologies Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“September 30, 2025, the Company received a second letter from Nasdaq granting the Company’s request for a 180-day extension to regain compliance with the Bid Price Rule. The Company now has until March 30, 2026, to meet the requirement. As part of the Company’s request for the 180-day extension, the Company notified Nasdaq that it intends to regain compliance with the Bid Price Rule by effecting a reverse stock split, if necessary. If at any time prior to March 30, 2026, the bid price of the Company’s common stock closes at $1 per share or more for a minimum of 10 consecutive business days, th”

Sky Quarry Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“September 25, 2025, Sky Quarry Inc. (the “Company”) received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted an additional 180-day period, or until March 23, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). As previously disclosed, on March 28, 2025, the Company was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Requirement because the closing bid price of the Company’s”

GRAPHJET TECHNOLOGY received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“September 2, 2025, the Company received a written notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that because the Company did not regain compliance with Nasdaq Listing Rule 5450(b)(2)(A), requiring that the Company maintain a minimum market value of its listed securities of $50,000,000 for 30 consecutive trading days, by September 1, 2025, Nasdaq will consider this deficiency in their decision regarding the Company’s continued listing on The Nasdaq Global Market. The Notice has no immediate effect on the listing of the Company’s ordinary shares on The Nasdaq G”

DT Cloud Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“September 25, 2025, DT Cloud Acquisition Corporation received a deficiency letter (“Notice”) from the Listing Qualifications Department of Nasdaq notifying DT Cloud Acquisition Corporation that for the last 30 consecutive business days, the minimum Market Value of Publicly Held Shares, as defined by Nasdaq (“MVPHS”), of DT Cloud Acquisition Corporation has been below the minimum $15 million requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Requirement”); and The Notice dated September 25, 2025, notified DT Cloud Acquisition Corpor”

VSEE HEALTH, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“sdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025. The Company is also not currently in compliance with Nasdaq Listing Rule 5550(b)(1) because the Company’s stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing as of December 31, 2024. The Company is working on remedying these deficiencies, but there can be no assurance that the Company will be eligible for the additional 180 calenda”

VSEE HEALTH, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“curities, including its common stock and public warrants, would be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq staff’s determination to delist its securities. As previously reported, the Company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025. The Company is also not currently in compliance with Nasdaq Listing Rule 5550(b)(1) because”

Adaptimmune Therapeutics PLC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“September 22, 2025, Adaptimmune Therapeutics plc (the “Company”) received a written notice from the Nasdaq Hearings Panel (the “Panel”) confirming that the Company has been granted an exception period to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”). ​ The Company has until December 1, 2025 to regain compliance with the Bid Price Rule. Failure to regain compliance by December 1, 2025 will result in the delisting of the Company’s American Depositary Shares from The Nasdaq Capital Market. ​ Forward-Looking Stat”

Longeveron Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 22, 2025, Longeveron Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the Company’s Class A common stock (“Common Stock”) did not meet the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) as a result of the closing bid price of the Company’s Common Stock for the last 30 consecutive business days. The Notice does not result in the immediate delisting of the Company’s Common Stoc”

Tevogen Bio Holdings Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“September 23, 2025, Tevogen Bio Holdings Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets Nasdaq’s $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”) for continued listing on Nasdaq based on the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the previous 30 consecutive business days. The notification received has no immediate eff”

GRAPHJET TECHNOLOGY received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1), 5450(a)(1)).

“September 24, 2025, the Company received a written notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires all listed companies to timely file all required period financial reports with U.S. Securities and Exchange Commission (the “ Periodic Filing Rule ”), and Nasdaq Listing Rule 5450(a)(1), which requires listed companies to maintain a minimum bid price of at least $1.00 per share for their primary equity security to remain listed (the “ Bid Price Rule ”), as required by the July”

Greenland Mines Ltd received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 19, 2025, Klotho Neurosciences, Inc. (the “Company”) received a delinquency notification letter (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) due to the failure of the Company’s common stock to maintain a minimum bid price of $1 per share for 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until March 18, 2026, to regain compliance. To regain compliance, prior to March 18, 2026, the closing bid price of the Company’s common stock must be a”

FlexShopper, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“ying the Company that, for a period of 30 consecutive business days, the bid price for the Company’s common stock, $0.0001 par value per share (the “Common Stock”) had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The letter has no immediate effect on the listing of the Common Stock, which continues to trade on The Nasdaq Global Market under the symbol “FPAY” at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has until March 17, 20”

SYNTEC OPTICS HOLDINGS, INC. received a nasdaq noncompliance notice notice regarding late filing.

“September 16, 2025, Syntec Optics Holdings, Inc. (the “Company”) is delayed in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025. NASDAQ exception will be allowed to enable the Company to regain compliance with all delinquent filings, but only for a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or October 13, 2025. The Company’s auditors have substantially completed their procedures for these periods. The remaining steps primarily re”

BioCardia, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 1, 2025, BioCardia, Inc. (the “Company,” “we,” “us” and “our”) received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its amount of stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1). As noted in the Original 8-K, the Company had until May 16, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on May 15, 2025”

Urgent.ly Inc. received a nasdaq delisting notice notice regarding other (rules 5550(b)).

“September 16, 2025, the Staff notified the Company that, based upon the Company’s continued non-compliance with the Rule as of September 15, 2025, the Company’s securities were subject to delisting from Nasdaq at the open of business on September 25, 2025 unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will automatically stay any further action by Nasdaq at least pending the conclusion of the hearing and the expiration of any extension period that may be granted by the Pan”

XBP Global Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).

“September 16, 2025, XBP Global Holdings, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”). The Letter notified the Company that, for a period of 30 consecutive business days, the bid price for the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) duri”

Rocky Mountain Chocolate Factory, Inc. received a nasdaq deficiency notice notice regarding other (rules 5605(b), 5605(c)).

“September 17, 2025, the Company received a notice from The Nasdaq Stock Market LLC (the “Notice”), notifying the Company that, as a result of the Resignation, the Company is not in compliance with the requirements under Nasdaq Listing Rule 5605 (the “Corporate Governance Requirements”), specifically: ● Nasdaq Listing Rule 5605(b), which requires, among other things, that a majority of the Company’s board of directors (the “Board”) be comprised of Independent Directors (as defined in Nasdaq Listing Rule 5605(a)(2)); and ● Nasdaq Listing Rule 5605(c), which requires, among other things, that the”

Vaxart, Inc. received a nasdaq delisting notice notice regarding other.

“September 19, 2025, the Company received a letter from the Office of the General Counsel of Nasdaq, stating that the Company’s securities will be delisted from Nasdaq as a result of the Company’s noncompliance with the Panel’s Conditions. Trading in the Company’s common stock on Nasdaq was suspended at the open of trading on July 8, 2025. The Company’s common stock is currently quoted on the OTCQX® Best Market under the symbol “VXRT.” SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the unde”

ZyVersa Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“dicating that the Panel had determined to delist the Company’s securities from Nasdaq and that trading in the Company’s securities would be suspended at the open of trading on July 17, 2025, due to the Company’s failure to regain compliance with the minimum bid price requirements under Listing Rule 5550(a)(2) . CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K (“Form 8-K”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of hi”

DIH HOLDING US, INC. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A)).

“ent in filing its Form 10-Q for the period ended June 30, 2025, and Form 10-K for the fiscal year ended March 31, 2025 (the “Form 10-K”, together with the Form 10-Q, the “Delinquent Reports”), so the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Reports Rule”), which requires the timely filing of all required periodic reports with the SEC. Further, the September 2, 2025 letter from Nasdaq stated that the Company’s securities were subject to delisting since it had not regained compliance with the minimum $50,000,000 MVLS thr”

DIH HOLDING US, INC. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“September 2, 2025 Nasdaq notified the Company that its securities were subject to delisting since it was not current in filing its Form 10-Q for the period ended June 30, 2025, and Form 10-K for the fiscal year ended March 31, 2025 (the “Form 10-K”, together with the Form 10-Q, the “Delinquent Reports”), so the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Reports Rule”), which requires the timely filing of all required periodic reports with the SEC. Further, the September 2, 2025 letter from Nasdaq stated that the Company’”

Roman DBDR Acquisition Corp. II received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 28, 2025, Roman DBDR Acquisition Corp. II (the “Company”) received a deficiency letter (the “Deficiency Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it was not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of not having filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Quarterly Report”). The Deficiency Notice has no immediate effect on the listing of the Company’s securitie”

INTERGROUP CORP received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).

“September 17, 2025, the Company received a confirmation from Nasdaq that the Company has regained compliance with Listing Rule 5550(b)(2). Nasdaq’s notice stated that, as of September 15, 2025, the Company had demonstrated 11 consecutive business days with a market value of listed securities above $35 million, thereby satisfying the requirement. As a result, the Panel granted the Company’s request for continued listing, and the matter is now closed. The Company’s common stock will continue to be listed and traded on The Nasdaq Capital Market under the symbol “INTG”.”

RYVYL Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1), 5605(c)(2)(A)).

“September 15, 2025, the Company provided notice to the Nasdaq Continued Listing Center that the Company is not currently in compliance with Nasdaq Listing Rule 5605(b)(1) (the “Majority Independent Board Requirement”) and Nasdaq Listing Rule 5605(c)(2)(A) (the “Audit Committee Composition Requirement”). The Company’s Board of Directors (“Board”) is currently comprised of two directors who are independent, Brett Moyer and Gene Jones, and two directors who are not independent, Fredi Nisan and George Oliva. One additional director, who satisfies Nasdaq’s independence requirements, is required for”

HeartSciences Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“osed. As previously disclosed in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on March 21, 2025, the Company previously received a letter from the Staff indicating that the Company was not in compliance with the requirements of Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders’ equity (the “Minimum Stockholders’ Equity Requirement”), and the Company did not otherwise meet the alternative requirements of market value of listed securiti”

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5460(a)(2), 5810(c)(3)(D)).

“September 11, 2025, Bio Green Med Solution, Inc. ( fka Cyclacel Pharmaceuticals, Inc.) received a letter from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that its 6% Convertible Exchangeable Preferred Stock (listed on the Nasdaq Capital Market under the symbol “BGMSP”) (the “Preferred Stock”) no longer complies with the requirement under Nasdaq Listing Rule 5460(a)(2) to maintain a minimum Market Value of Publicly Held Shares (as such terms are defined under the Nasdaq Listing Rules, “MVPHS”) of $1 million. The Staff’s”

Neuphoria Therapeutics Inc. received a nasdaq extension granted notice regarding shareholders (rules 5620(a)).

“September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension of 180 calendar days (the “ Compliance Period ”) from the end of the Company’s fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. To this end, the Company intends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy statement and notice of shareholder meeting related to the Company’s 2025 annual general shareholder meeting, and further intends to hold such”

Wetouch Technology Inc. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).

“ss days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq. The Company had a period of 180 calendar days, or until January 12, 2026, to regain compliance with the Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). On September 15, 2025, the Company received a letter from Nasdaq notifying the Company that the Staff had determined that the closing price of the Company’s common stock was $1.00 or greater for the requisite period of time and that the Company had regained complia”

Wetouch Technology Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“ss days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq. The Company had a period of 180 calendar days, or until January 12, 2026, to regain compliance with the Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). On September 15, 2025, the Company received a letter from Nasdaq notifying the Company that the Staff had determined that the closing price of the Company’s common stock was $1.00 or greater for the requisite period of time and that the Company had regained complia”

Profusa, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“September 11, 2025, Profusa, Inc. (the “ Company ”) received a notice (the “ MVLS Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, based upon its review of the market value of listed securities (“ MVLS ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), from July 29, 2025 to September 10, 2025, the Company no longer meets Nasdaq Listing Rule 5450(b)(2)(A), which requires companies listed on the Nasdaq Global Market to maintain a minimum MVLS of $50,000,000. Pursuant to Nasdaq Listing R”

Healthcare Triangle, Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5635(a)(1)).

“September 15, 2025, Healthcare Triangle, Inc. (the “Company”) received a letter from the Nasdaq Stock Market (“Nasdaq”) indicating that the Company had previously failed to comply with Nasdaq Listing Rule 5635(a)(1), which requires shareholder approval prior to the issuance of common stock representing 20% or more of the pre-transaction outstanding voting power or shares in connection with an acquisition. Nasdaq’s determination was based on the Company’s Form 8-K filed June 23, 2025, which disclosed that the Company agreed to issue approximately 345,622,120 shares of common stock (prior to adj”

VYNE Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 11, 2025, VYNE Therapeutics Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The notification does not impact the listing of the Company’s Common Stock on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)”

Adaptimmune Therapeutics PLC received a nasdaq deficiency notice notice regarding other (rules 5550(b)(2)).

“September 11, 2025, Adaptimmune Therapeutics plc (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 32 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) was less than the $35.0 million minimum required for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the “MVLS Listing Rule”). Additionally, as of the date of the Notice, the Company did not mee”

Adaptimmune Therapeutics PLC received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“September 11, 2025, Adaptimmune Therapeutics plc (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 32 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) was less than the $35.0 million minimum required for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the “MVLS Listing Rule”). Additionally, as of the date of the Notice, the Company did not mee”

CXApp Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 11, 2025, CXApp Inc. (the “Company”) received a letter (the “Minimum Bid Price Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the closing bid price for the Company’s common stock (the “Common Stock”) has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Nasdaq Minimum Bid Price Requirement”). The Minimum Bid Price Notice has no immediate effect on the listing of the”

Longevity Health Holdings, Inc. received a nasdaq delisting notice notice regarding other (rules 5550(b)(2)).

“September 10, 2025, Longevity Health Holdings, Inc., a Delaware corporation (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company had not cured the previously reported deficiency with respect to Nasdaq Listing Rule 5550(b)(2) and as a result, the Panel determined to delist the Company’s securities from the Nasdaq Capital Market at the open of trading on September 12, 2025. The Company’s common stock and warrants began trading publicly on the over-the-counter markets operated by OTC Markets Group, Inc. (“OTC”) at the open of trading on S”

Blink Charging Co. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“September 9, 2025, the Company received written notice from Nasdaq informing the Company that it has regained compliance with Rule 5550(a)(2) and that this matter is now closed.”

CYPHERPUNK TECHNOLOGIES INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 8, 2025, to regain compliance with Rule 5550(a)(2) by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. Additionally, Nasdaq notified the Company that it might be eligible for an additional compliance period of 180 calendar days if, on September 8, 2025, the Company met the continued listing requirement for market value of publicly held shares and all other applicable standards for initial listing on the Nasdaq Capital Market (with the exception of the closing bid price requirement) based on the Company’s then most recent publi”

Sadot Group Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 9, 2025, Sadot Group Inc. (the “Company”) received a letter (the “Staff Determination”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the Company’s common stock had a closing bid price of less than $1.00 per share over the previous 30 consecutive business days from July 28, 2025 through September 8, 2025, and, as a result, does not comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Company is not eligible for the 180-calendar day compliance period”

GameSquare Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 10, 2025, GameSquare received a letter (the “Minimum Bid Price Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying GameSquare that for the last 30 consecutive business days, the closing bid price for GameSquare’s common stock (the “Common Stock”) has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Nasdaq Minimum Bid Price Requirement”). The Minimum Bid Price Notice has no immediate effect on the listing of the Common Stock, and”

Quetta Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“September 3, 2025, Quetta Acquisition Corporation (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company no longer meets the requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A). Based on Nasdaq’s review, the Company’s MVLS has been below $50,000,000 for the last 30 consecutive business days. Accordingly, the Company is not in compliance with the continued listing requi”

Enlightify Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“August 27, 2025, the New York Stock Exchange (“NYSE”) notified Enlightify Inc. (the “Company”) that the 30-trading-day average closing price of the Company’s common stock had fallen below $1.00 per share, the minimum average share price required for continued listing of the Company’s common stock on the NYSE under Rule 802.01C of the NYSE Listed Company Manual. Pursuant to applicable NYSE rules, the Company has responded to the NYSE by letter of September 9, 2025 informing the NYSE of its intent to cure the share price deficiency for the purpose of returning to compliance with the continued li”

OSR Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 5, 2025, OSR Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company’s securities, which will continue to trade on The Nasdaq Capital Market under the symbols “OSRH” and”

ORION ENERGY SYSTEMS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“September 8, 2025, the Company received a written notification from the Staff indicating that the Company has regained compliance with the Minimum Bid Price Rule. Consequently, the Company is now in compliance with all applicable listing standards of, and will continue to be listed on, the Nasdaq Capital Market. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORION ENERGY SYSTEMS, INC. Date: September 8, 2025 By: /s/ J. Per Brodin J. Per Brodin Chi”

AIxCrypto Holdings, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“September 4, 2025, Qualigen Therapeutics, Inc. (the “Company”) received a written decision (the “Decision Letter”) from the Nasdaq Hearings Panel (the “Panel”) in response to the Company’s August 19, 2025 update and request for a compliance determination with respect to the Panel’s July 24, 2025 decision, as amended. As previously disclosed, on July 24, 2025, the Panel granted the Company an exception to remain listed on The Nasdaq Capital Market, conditioned on demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”), which requires companies to maintain stockholders’”

Aqua Metals, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“September 4, 2025 confirming the Company had regained compliance with minimum bid requirement in Listing Rule 5550(a)(2). The Company will be subject to a mandatory panel monitor for a period of one year ending September 4, 2026. If, within that one-year monitoring period, the Nasdaq staff finds the Company again out of compliance with the minimum bid requirement, the Company will not be eligible for any compliance grace period under the Nasdaq Listing Rules in order to regain compliance with Listing Rule 5550(a)(2), and, consequently, the Company would be subject to a delist determination fro”